US.EW · Edwards Lifesciences

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.572632794457275,
        "turnoverUsdM": 347.04084,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.EW",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 82.1442,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 2.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 5.1,
      "take_profit_price": 91.468,
      "target_multiplier": 1.9,
      "technical_strength": 1.73,
      "take_profit_percent": 5.6
    },
    "positionPoints": 1.6,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.14526558891455,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 61.8,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 54.8,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 86.464,
    "ma50": 88.4196,
    "close": 86.6,
    "prevClose": 88.1,
    "avgVolume20": 3764195,
    "volumeRatio": 1.06,
    "changePercent": -1.7
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": 0.01631263936157734,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 1.061135648692447,
      "ret_points": 4,
      "vol_points": 2,
      "range_ratio": 1.165384028119287,
      "volat_points": 0,
      "day_range_pct": 0.026674411085450423,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 61.8,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.7,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 54,
        "contribution": 2.7
      },
      {
        "raw": 8.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 42,
        "contribution": 8.4
      },
      {
        "raw": 8.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 57.33,
        "contribution": 8.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 68,
        "contribution": 6.8
      },
      {
        "raw": 18.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 61,
        "contribution": 18.3
      },
      {
        "raw": 8,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 80,
        "contribution": 8
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 54.8,
    "details": [
      "基本面分析總分: 2.7/5分",
      "資金流分析總分: 8.4/20分",
      "市場環境分析總分: 8.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.8/10分",
      "技術信號分析總分: 18.3/30分",
      "情緒分析: 8/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.7,
      "資金流": 8.4,
      "市場環境": 8.6,
      "情緒分析": 8,
      "技術信號": 18.3,
      "風險管理": 6.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 2,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 347.04084,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 1.6,
          "obvPoints": 0.8,
          "vwapPoints": 2.4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.EW",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.46
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 742.51900315,
                "ma50": 726.7734006600002,
                "name": "QQQ",
                "close": 709.79999,
                "points": 0.4
              },
              "spy": {
                "ma20": 771.1839966499999,
                "ma50": 768.5017965800001,
                "name": "SPY",
                "close": 763.25,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.572632794457275,
          "atrPoints": 3,
          "cciPoints": 2.4,
          "vixPoints": 2.4,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "優秀",
        "items": {
          "sentiment": {
            "score": 8,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 2,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 2.4
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142266550,
                "url": "https://finnhub.io/api/news?id=da0f8c9693d571ce918d448e54f2a4e1f344477545ea3925d87467465be4b61c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences recently outlined its structural heart growth plan, emphasizing transcatheter valve platforms such as TAVR and TMTT, alongside the impact of updated Medicare coverage that could enable 100–200 additional U.S. centers to perform TAVR procedures. A particularly important takeaway is Edwards’ ambition to build a multibillion-dollar transcatheter mitral and tricuspid business by 2030, anchored by PASCAL, EVOQUE, and Sapien M3 technologies that aim to address complex...",
                "category": "company",
                "datetime": 1789769713,
                "headline": "How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions"
              },
              {
                "id": 142260140,
                "url": "https://finnhub.io/api/news?id=e456714e92954de98b33d6053fadb104ecebefa6f418a514898827cc6f127659",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences has delivered a mixed share price story, with the stock up 18.4% over the past year but still down sharply over a 5 year span. This puts the focus squarely on what investors are paying for its future cash flows. With fresh policy news around its core heart valve franchise and a current share price of US$88.25, the key issue is whether the company’s cash generation can support where the stock trades today. Over 5 years the share price has declined 27.1%, which raises the...",
                "category": "company",
                "datetime": 1789755142,
                "headline": "Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion"
              }
            ],
            "raw_source": [
              {
                "id": 142950181,
                "url": "https://finnhub.io/api/news?id=96549fc3169af14a5b37e1838856ce6d4ea231da47ab79fb2b1b643ba4673a05",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "The U.S. Food and Drug Administration (FDA) issued a high-risk early alert after Edwards Lifesciences Corp. (NYSE:EW) recalled specific lots of its Commander M delivery systems due to reports of balloons bursting during procedures, resulting in one death and a serious injury. Recall Of Commander M Delivery Systems The delivery systems help implant a replacement mitral heart valve through blood vessels, bypassing the need for open-chest surgery. However, the company received three distinct report",
                "category": "company",
                "datetime": 1792163582,
                "headline": "FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death"
              },
              {
                "id": 142945843,
                "url": "https://finnhub.io/api/news?id=efc985c8849482b1c5cb63a903feab7a147146983249315764c2b32ff17b12da",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "An issue with the delivery component of Edwards’ SAPIEN M3 TMVR system has been associated with one patient death and one serious injury as of 5 October.",
                "category": "company",
                "datetime": 1792151246,
                "headline": "Edwards’ SAPIEN M3 delivery system linked to patient death in FDA alert"
              },
              {
                "id": 142947552,
                "url": "https://finnhub.io/api/news?id=cce961828583081443d280e38e71db1b045f33b20765ffc7c43f7023022e5860",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-transcatheter-mitral-valve-delivery-system-issue-edwards-lifesciences ",
                "category": "company",
                "datetime": 1792122647,
                "headline": "Reported Earlier, Edwards Lifesciences Tells Customers To Remove Four Lots Of Commander M Delivery Systems For SAPIEN M3; FDA Flags Potentially High-Risk Issue"
              },
              {
                "id": 142882630,
                "url": "https://finnhub.io/api/news?id=5e4289c0c9b96dfa1e95a00694f6be0915f8672c2b831308bed3a3fce09f0551",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.",
                "category": "company",
                "datetime": 1791979740,
                "headline": "Bet on These Healthcare ETFs to Benefit From the Aging US Population"
              },
              {
                "id": 142821843,
                "url": "https://finnhub.io/api/news?id=5b892fbff9720a6bd56b824deb05c3dc8dcd697cd77783988b10fb0eaab315fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences is set to report its Q3 earnings next month, with analysts expecting single-digit year-over-year EPS growth.",
                "category": "company",
                "datetime": 1791795397,
                "headline": "Edwards Lifesciences Earnings Preview: What to Expect"
              },
              {
                "id": 142730419,
                "url": "https://finnhub.io/api/news?id=5741fde32d2d428cfb091510e2b9dc970e9a9cdc9798a0a9de13df26fb600389",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "EW",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1791477301,
                "headline": "Stay informed with the top movers within the S&P500 index on Thursday."
              },
              {
                "id": 142703057,
                "url": "https://finnhub.io/api/news?id=cbb9c770540f123bf7f8169895da328689f42faa5286fda4eeaa46990dd6c523",
                "image": "",
                "source": "Fintel",
                "related": "EW",
                "summary": "",
                "category": "company",
                "datetime": 1791417130,
                "headline": "Barclays Initiates Coverage of Edwards Lifesciences at Overweight"
              },
              {
                "id": 142699429,
                "url": "https://finnhub.io/api/news?id=c7662009b9ace98cff37eb649fd5c094fe1d8023fc1a1ff779048499c9832520",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Intuitive Surgical SP platform is gaining momentum as procedures, utilization and placements rise, with expanding indications and global adoption fueling growth.",
                "category": "company",
                "datetime": 1791394260,
                "headline": "Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?"
              },
              {
                "id": 140420211,
                "url": "https://finnhub.io/api/news?id=c9045c53ac19ad80d94a07c2e8320fa134ac76c18ad5824d79898864952688d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Intel downgraded, Marvell upgraded: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1791381613,
                "headline": "Intel downgraded, Marvell upgraded: Wall Street's top analyst calls"
              },
              {
                "id": 142689571,
                "url": "https://finnhub.io/api/news?id=7328d68ff960ea6cd6cc1d7e84ad93210c84e804ca09c005e1de805c1458a6df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "IRVINE, Calif., October 07, 2026--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will host a conference call at 5:00 p.m. ET that day to discuss those results.",
                "category": "company",
                "datetime": 1791367200,
                "headline": "Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026"
              },
              {
                "id": 142696722,
                "url": "https://finnhub.io/api/news?id=b571dd0f7ba78a624d470fa3b3093c847514e128ce54822d2c1d0f3490f79271",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Barclays  analyst Christopher Pasquale   initiates coverage on Edwards Lifesciences (NYSE:EW) with a Overweight rating and announces Price Target of $110.",
                "category": "company",
                "datetime": 1791362408,
                "headline": "Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110"
              },
              {
                "id": 142632289,
                "url": "https://finnhub.io/api/news?id=5e79a351c69253cee95dc15b7a09a3b5363e19ef80d37e125eab80d72c621996",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "IRVINE, Calif., October 05, 2026--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The meeting will include a live Q&A session with physicians and members of the Edwards management team.",
                "category": "company",
                "datetime": 1791194400,
                "headline": "Edwards Lifesciences to Host Investor Event in Conjunction With TCT"
              },
              {
                "id": 142614627,
                "url": "https://finnhub.io/api/news?id=8655f8ec1bb477449776d78501af9ab82fe6b743d6ab33f1f8d7997fe0bbe8ef",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/02/Doctors--Tablet-And-People-With-Discussi.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Edwards Lifesciences earned FDA approval for its AUTUS pediatric heart valve, designed to expand as young patients grow.",
                "category": "company",
                "datetime": 1790937962,
                "headline": "Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart Valve"
              },
              {
                "id": 142589114,
                "url": "https://finnhub.io/api/news?id=80eebecc20b73e3685f3c3092f41f338a5253af972377b06c0dc5ce304802ac8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/02/Bangkok--Thailand---July-2--2017nike-Cla.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Nike falls on weak revenue; Synaptics jumps on $123 ON deal; AsiaStrategy surges on tokenization pact; Mangoceuticals drops.",
                "category": "company",
                "datetime": 1790914563,
                "headline": "Nike, Synaptics And 3 Stocks To Watch Heading Into Friday"
              },
              {
                "id": 142563009,
                "url": "https://finnhub.io/api/news?id=b0ab83642594294ce72c45514fe4296905c2602deb7307b9dddd9eaf37adf90a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "IRVINE, Calif., October 01, 2026--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement.",
                "category": "company",
                "datetime": 1790886360,
                "headline": "Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients"
              },
              {
                "id": 142590120,
                "url": "https://finnhub.io/api/news?id=17619dfabefb34c722fa720a4545f003a4542ab1a2e12bc371a4dd0e88326aff",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Edwards Lifesciences (NYSE:EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with",
                "category": "company",
                "datetime": 1790872027,
                "headline": "Edwards Lifesciences Says FDA Approves AUTUS Size-Adjustable Valve, Surgical Pulmonary Valve Designed For Pediatric Patients With Congenital Heart Disease"
              },
              {
                "id": 142266550,
                "url": "https://finnhub.io/api/news?id=da0f8c9693d571ce918d448e54f2a4e1f344477545ea3925d87467465be4b61c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences recently outlined its structural heart growth plan, emphasizing transcatheter valve platforms such as TAVR and TMTT, alongside the impact of updated Medicare coverage that could enable 100–200 additional U.S. centers to perform TAVR procedures. A particularly important takeaway is Edwards’ ambition to build a multibillion-dollar transcatheter mitral and tricuspid business by 2030, anchored by PASCAL, EVOQUE, and Sapien M3 technologies that aim to address complex...",
                "category": "company",
                "datetime": 1789769713,
                "headline": "How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions"
              },
              {
                "id": 142260140,
                "url": "https://finnhub.io/api/news?id=e456714e92954de98b33d6053fadb104ecebefa6f418a514898827cc6f127659",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences has delivered a mixed share price story, with the stock up 18.4% over the past year but still down sharply over a 5 year span. This puts the focus squarely on what investors are paying for its future cash flows. With fresh policy news around its core heart valve franchise and a current share price of US$88.25, the key issue is whether the company’s cash generation can support where the stock trades today. Over 5 years the share price has declined 27.1%, which raises the...",
                "category": "company",
                "datetime": 1789755142,
                "headline": "Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion"
              },
              {
                "id": 142251945,
                "url": "https://finnhub.io/api/news?id=37512db8dc48a1b609e465c892d8209fa7791765c124efa21b1a41a2ce7135c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "The global interventional cardiology devices market is forecast to grow from USD 31.12 billion in 2026 to USD 42.39 billion by 2031, at a 6.4% CAGR. Growth is driven by rising cardiovascular disease, aging populations, demand for minimally invasive procedures, better healthcare access, and advances in stents, imaging and catheter technologies. Plain angioplasty balloons, embolic protection devices, guidewires and hospitals will see strong growth, while Asia Pacific is set to be the fastest-growi",
                "category": "company",
                "datetime": 1789727580,
                "headline": "Interventional Cardiology Devices Market by Type, End User - Global Forecast to 2031"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 2,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 2.4,
            "source_article_count": 19,
            "discarded_article_count": 17
          },
          "sentimentPoints": 8
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 18.3,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.1,
          "macdPoints": 3.2,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.1,
            "vcp_reason": "波幅收縮(10.5%→6.9%)；靠近20日高位；升放量(近10日3日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 3603090,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 3871300,
              "avg_vol_20": 3776520,
              "avg_vol_30": 3603090,
              "range_pct_10": 0.06905311778290982,
              "range_pct_20": 0.08348729792147795,
              "range_pct_30": 0.10508083140877593,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.0744388844019994,
              "dist_to_20d_high": 0.03412893151907208,
              "down_shrink_days": 2,
              "breakout_level_20d": 89.66,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6571428571428564
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.572632794457275,
              "turnoverUsdM": 347.04084,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.EW",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 82.1442,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 2.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 5.1,
            "take_profit_price": 91.468,
            "target_multiplier": 1.9,
            "technical_strength": 1.73,
            "take_profit_percent": 5.6
          },
          "positionPoints": 1.6,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.14526558891455,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 71.43,
    "atr": {
      "atr": 2.2279,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.57
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 47.94
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0464
    },
    "kdj": {
      "d": 61.91,
      "j": 88.02,
      "k": 70.61,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 48.3
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 33601200,
      "recentSlope": -513160,
      "previousSlope": -81880
    },
    "rsi": 49.32,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 88.8701,
      "position": "SAR喺價上",
      "distancePct": 2.62,
      "previousTrend": "下降"
    },
    "ma50": 88.4196,
    "macd": {
      "macd": -0.35648871763694956,
      "trend": "看漲",
      "signal": -0.5485227218642067,
      "histogram": 0.19203400422725714
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 6,
      "value": 86.345,
      "position": "連續1-2日>VWAP",
      "consecutiveAbove": 2
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.06,
      "score": 6,
      "avgVolume": 3764195,
      "currentVolume": 4007400
    },
    "derived": {
      "ma20": 86.464,
      "ma50": 88.4196,
      "prevClose": 88.1,
      "avgVolume10": 4031200,
      "avgVolume20": 3764195,
      "changePercent": -1.7,
      "avgVolumeForScore": 3764195
    },
    "ma_cross": {
      "ma20": 86.464,
      "ma50": 88.4196,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 86.547,
      "prevMa50": 88.474,
      "spreadPct": 2.21,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 84.1233,
      "upper": 88.8047,
      "position": "上半部"
    },
    "rsi_short": 65.53,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.06
    }
  }
}

{
  "close": 86.6,
  "volume": 4007400,
  "changePercent": -1.7
}